Starpharma expands its Drug Delivery Program with AstraZeneca

7 April 2014

Melbourne, Australia; Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced the signing of a second, expanded agreement with AstraZeneca in the field of cancer medicine using Starpharma's proprietary DEP™ dendrimer drug delivery technology.

The agreement follows on from an evaluation by AstraZeneca which began in September 2012 of Starpharma's delivery technology. The new agreement will see the application of Starpharma's technology to a cancer drug, from AstraZeneca's pipeline.

Under the new agreement, AstraZeneca will provide funding for a preclinical stage cancer research program to be conducted jointly.

Starpharma uses its DEP™ technology to improve the performance of pharmaceuticals.  Dendrimer-enhanced versions of drugs have been found to be superior to the unmodified drugs in pre-clinical studies, often having improved efficacy and fewer side effects or toxicities.

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.